Jesse Isenstadt, DO
Internal Medicine · Kennewick, WANPI 1336508266
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $325 of the $364 with a category attached, or 89.0%. It is spread thinly across 10 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $144 and has fallen 62.8% since, to $54 in 2024.
Across 16 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$75
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$55
- Gilead$46
- Astellas Pharma US Inc$40
- E.r. Squibb & Sons, L.L.C.$37
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$37
- plus $74 from 4 others
What the payments were for
- Food & beverage$32589%
- Education$4011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $75 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $55 |
| Gilead | 1 | $46 |
| Astellas Pharma US Inc | 1 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| AbbVie | 1 | $28 |
| Amgen | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$364 in reported general payments places this provider in the 80th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $6,436 |
| Ranolazine ErRanolazine | 12 | $369 |
| Atorvastatin Calcium | 16 | $153 |
| Amlodipine Besylate | 39 | $147 |
| Metoprolol Succinate | 25 | $141 |
| ClopidogrelClopidogrel Bisulfate | 14 | $114 |
| Lisinopril | 17 | $106 |
| Cefdinir | 17 | $89 |
| Furosemide | 17 | $38 |
| Prednisone | 18 | $28 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Kennewick
- Nadia ToshaniKennewick$7K
- Peter ShalitSeattle$1M
- Lawrence LoebBellevue$784K
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.